- Home
- SMTI vs CANF Comparison
SMTI vs CANF Comparison
Compare SMTI & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTI
- CANF
- Stock Information
- Founded
- SMTI 1982
- CANF 1994
- Country
- SMTI United States
- CANF Israel
- Employees
- SMTI N/A
- CANF N/A
- Industry
- SMTI Medical/Dental Instruments
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- SMTI Health Care
- CANF Health Care
- Exchange
- SMTI Nasdaq
- CANF Nasdaq
- Market Cap
- SMTI 273.6M
- CANF 14.8M
- IPO Year
- SMTI N/A
- CANF N/A
- Fundamental
- Price
- SMTI $28.81
- CANF $1.04
- Analyst Decision
- SMTI Strong Buy
- CANF Strong Buy
- Analyst Count
- SMTI 2
- CANF 2
- Target Price
- SMTI $49.50
- CANF $14.00
- AVG Volume (30 Days)
- SMTI 40.4K
- CANF 138.7K
- Earning Date
- SMTI 08-11-2025
- CANF 04-14-2025
- Dividend Yield
- SMTI N/A
- CANF N/A
- EPS Growth
- SMTI N/A
- CANF N/A
- EPS
- SMTI N/A
- CANF N/A
- Revenue
- SMTI $91,569,883.00
- CANF $674,000.00
- Revenue This Year
- SMTI $23.53
- CANF $461.72
- Revenue Next Year
- SMTI $5.93
- CANF N/A
- P/E Ratio
- SMTI N/A
- CANF N/A
- Revenue Growth
- SMTI 34.65
- CANF N/A
- 52 Week Low
- SMTI $25.86
- CANF $0.98
- 52 Week High
- SMTI $39.08
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- SMTI 48.30
- CANF 44.04
- Support Level
- SMTI $27.80
- CANF $1.01
- Resistance Level
- SMTI $28.50
- CANF $1.09
- Average True Range (ATR)
- SMTI 1.15
- CANF 0.05
- MACD
- SMTI 0.13
- CANF 0.00
- Stochastic Oscillator
- SMTI 55.97
- CANF 33.28
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).